BMY
EquityBristol-Myers Squibb Company
Health Care · Drug Manufacturers - General
$62.37
+62.37 (+0.00%)
Open
N/A
Day Range
$61.18 - $62.68
52W Range
$42.52 - $63.33
Volume
8M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
ORMP: Enabling Participation in Both ORMP & LFWD Businesses Expected to Enhance Shareholder Value
Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| 001540.KQ | AHN-GOOK PHA | $8,070.00 | N/A | 5.45% | +0.00% |
| ABBV | AbbVie Inc. | $232.06 | N/A | 2.87% | +0.00% |
| LLY | Eli Lilly and Company | $1,052.20 | N/A | 0.59% | +0.00% |
| NVO | Novo Nordisk A/S | $37.46 | N/A | 4.49% | +0.00% |
| EJG.F | EBOS Group Ltd. R | $11.70 | N/A | 5.14% | +0.00% |
| 5889.T | JAPAN EYEWEAR HOLDINGS CO LTD | $1,998.00 | N/A | 4.20% | +0.00% |
| 0332.KL | TOPVISN | $0.17 | N/A | 11.76% | +0.00% |
| ABT | Abbott Laboratories | $116.32 | N/A | 2.06% | +0.00% |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
www.bms.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
Dividend History
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Dividend Growth
1Y CAGR
+3.3%
3Y CAGR
+4.7%
5Y CAGR
N/A
10Y CAGR
N/A
Loading financial data...
Revenue & Earnings
No financial statement data available for BMY.